$AMGN · AMGEN INC SEC Filings
Position Tracker tracks 11 SEC EDGAR filings for AMGEN INC ($AMGN) from August 4, 2026 through November 3, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 2 Form 8-K current event disclosures, and 8 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$AMGN 8-K — AMGEN INC
Amgen's earnings reveal a bifurcated portfolio: newer drugs are surging but legacy blockbusters Prolia and XGEVA are in freefall from biosimilars, testing whether the growth pip…
$AMGN 3 — Amgen Inc.
This SEC filing is a Form 3 initial statement of beneficial ownership for Thomas J.W. Dittrich, identified as Amgen Inc.'s Executive Vice President and Chief Financial Officer.…
$AMGN 4 — Amgen Inc.
Amgen Inc. filed a Form 4 disclosing stock transactions by Rachna Khosla, its Senior Vice President of Business Development. On August 11, 2026, she sold 2,000 shares of Amgen c…
$AMGN 4 — Amgen Inc.
Amgen Inc. filed a Form 4 on August 12, 2026, reporting a change in beneficial ownership for Matthew C. Busch, the company’s Vice President, Finance and Chief Accounting Officer…
$AMGN 4 — Amgen Inc.
On August 7, 2026, Omar Ishrak, a director of Amgen Inc., reported an acquisition of 85.1685 shares of Amgen common stock at a price of $0. Following the reported transaction, h…
$AMGN 4 — Amgen Inc.
Amgen Inc. filed a Form 4 reporting a change in beneficial ownership for director Charles M. Holley. On August 7, 2026, Holley acquired 103.4189 shares of Amgen common stock at…
$AMGN 4 — Amgen Inc.
Amgen Inc. filed a Form 4 reporting a change in beneficial ownership by Michael V. Drake, a director of the company. The filing states that on August 7, 2026, Drake acquired 63.…
$AMGN 4 — Amgen Inc.
On August 6, 2026, Derek Miller, Senior Vice President of Human Resources at Amgen Inc., reported changes in beneficial ownership on a Form 4. He exercised two non-qualified sto…
$AMGN 4 — Amgen Inc.
Nancy A. Grygiel, Senior Vice President and Chief Compliance Officer of Amgen Inc., reported transactions in Amgen common stock on August 6, 2026. She exercised non-qualified st…
$AMGN 10-Q — Amgen Inc.
On August 5, 2026, Amgen Inc. filed its Form 10-Q for the quarter ended June 30, 2026. The report provides unaudited financial results for the three and six months ended June 30…
$AMGN 8-K — Amgen Inc.
Amgen’s 8-K filing included its earnings release for the second quarter of 2026. The company reported total revenues of $10.1 billion, up 10 percent from the prior-year period,…